Business Context and Reporting Period
This Form 6-K filing by NLS Pharmaceutics Ltd. (also referenced as Newcelx Ltd. in metadata) covers the month of June 2025. The report details the amendment and subsequent closing of a private placement offering initially agreed upon in March 2025.
Key Financial Metrics
The filing focuses on capital raising activities rather than operational financial performance. No revenue, profit, cash flow, or margin data is provided in this document.
- Initial Closing (March 2025): Issued 1,212,122 preferred shares and warrants for 787,880 common shares for gross proceeds of $2 million.
- Second Closing (June 27, 2025): Issued 606,061 preferred participation certificates (PPCs) and warrants for 393,939 common shares for gross proceeds of $1 million.
- Side Letter Transaction: Issued pre-funded warrants for 485,000 common shares to Alpha Capital Anstalt in lieu of preferred shares.
- Conversion/Exercise Prices: Preferred shares/PPCs at $1.65 per share; Warrants at $1.80 per share.
Material Changes
The primary material change is the execution of an amendment on June 26, 2025, to the Securities Purchase Agreement. This amendment modified the terms of the optional $1 million tranche, requiring the issuance of Preferred Participation Certificates (PPCs) instead of preferred shares, while maintaining identical rights and privileges. Additionally, a side letter was executed with Alpha Capital Anstalt to alter the compensation structure for price protection and registration obligations.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on operational outlook, or specific risk factors beyond standard securities law disclosures. The securities were offered under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D. The filing notes that the securities are unregistered and may not be offered or sold in the United States except pursuant to an effective registration statement or applicable exemption.
Investor Verification Checklist
- Verify the exact rights and privileges of the newly issued Preferred Participation Certificates (PPCs) compared to the original preferred shares.
- Confirm the total number of outstanding warrants and their dilution impact on existing shareholders.
- Review the specific terms of the side letter with Alpha Capital Anstalt regarding the pre-funded warrants.
- Check for any subsequent filings regarding the registration status of these securities for U.S. trading.